The Value of Platelet-Rich Plasma in Chronic Midportion Achilles Tendinopathy: a Double-blind Randomized Clinical Trial (PRICT)
Primary Purpose
Achilles Tendinopathy
Status
Completed
Phase
Phase 4
Locations
Netherlands
Study Type
Interventional
Intervention
PRP Injection with eccentric exercises
Placebo Injection with eccentric exercises
Sponsored by
About this trial
This is an interventional treatment trial for Achilles Tendinopathy
Eligibility Criteria
Inclusion criteria
- Clinical diagnosis "chronic midportion Achilles tendinopathy"
- Age 18-70 years
Exclusion criteria
- Clinical suspicion of insertional disorders (pain at the site of the insertion of the Achilles tendon on the calcaneum)
- Clinical suspicion of an Achilles tendon rupture (Thompson test abnormal and palpabel "gap")
- Clinical suspicion of plantar flexor tenosynovitis (posteromedial pain when the toes are plantar flexed against resistance)
- Clinical suspicion of n.suralis pathology (sensitive disorder in the area of the sural nerve)
- Clinical suspicion of peroneal subluxation (visible luxation of the mm. Peroneï spot in combination with localized pain)
- Suspicion of internal disorders: spondylarthropathy, gout, hyperlipidemia, Rheumatoid Arthritis and sarcoidosis.
- Condition that prevents the patients from executing an active exercise programme
- Patient has already performed eccentric exercises, according to the schedule of Alfredson et al (12 weeks)
- Patient has already received an injection of PRP for this injury
- Patient does not wish, for whatever reason, to undergo one of the two treatments
- Known presence of a pregnancy
- Condition of the Achilles tendon caused by medications (arising in relation to moment of intake), such as quinolones and statins
Sites / Locations
- Erasmus Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
1
2
Arm Description
Combination of eccentric exercises and injection of PRP
Combination of eccentric exercises and physiological saline injection
Outcomes
Primary Outcome Measures
VISA-A Score
Secondary Outcome Measures
Ultrasonographic Tissue Characterization
Complications
Power doppler sound
Patient satisfaction
Return to sport
Full Information
NCT ID
NCT00761423
First Posted
September 25, 2008
Last Updated
May 17, 2017
Sponsor
Zimmer Biomet
Collaborators
Erasmus Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT00761423
Brief Title
The Value of Platelet-Rich Plasma in Chronic Midportion Achilles Tendinopathy: a Double-blind Randomized Clinical Trial
Acronym
PRICT
Official Title
The Value of Platelet-Rich Plasma in Chronic Midportion Achilles Tendinopathy: a Double-blind Randomized Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
August 2008 (undefined)
Primary Completion Date
February 2009 (Actual)
Study Completion Date
August 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zimmer Biomet
Collaborators
Erasmus Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study will be a double-blind randomized single-center clinical trial comparing 3 treatment groups with chronic midportion Achilles tendinopathy.
Detailed Description
Introduction- Overuse injury of the Achilles tendon is a common entity in athletes and older athletes are at an increased risk. When the exact origin of tendon pain is unclear, the term tendinopathy is preferred. Most accepted treatment at this moment is an eccentric exercise programme, according to the Dutch guidelines. However, a recent systematic review on the effectiveness of eccentric exercises to treat lower extremity tendinoses concluded that it is unclear whether eccentric exercises are more effective than other forms of treatment.
Recent studies described new treatment strategies in tendinopathies, such as the use of platelet-rich plasma (PRP). Platelets can participate actively in tissue repair processes and stimulate the release of several growth factors. Recently, it was found that platelet-rich plasma clot releasate stimulates cell proliferation, collagen deposition, and enhances the gene expression of matrix degrading enzymes and endogenous growth factors by human tendon cells in vitro. The only published clinical cohort study in tendon research reported 93% reduction of pain for PRP-treated patients with chronic elbow tendinosis. Also on short term follow-up, the PRP injection was more beneficial than injection with an anaesthetic agent.
Aim- To monitor the potential clinical improvement of chronic midportion Achilles tendinopathy after injection with PRP and to evaluate the recovery process in time using a new Ultrasonographic method (Ultrasonographic Tissue Characterisation).
Hypothesis: The average VISA-A score is higher in the patient group treated with eccentric exercise therapy in combination with a PRP injection in comparison with the group treated with a saline injection in combination with eccentric exercises.
Study population- In total, 54 patients with symptomatic Achilles tendinopathy will be included in the study.
Study design- The study will be a double-blind randomised single-centre clinical trial comparing 2 treatment groups. The researcher, the sports medicine physician and the patients will be blinded to the received therapy.
Therapy- All patients will perform a heavy load eccentric exercise programme, consisting of 180 repetitions daily. The patients will be randomised into 2 treatment groups: ultrasound guided intratendinous saline injection with eccentric exercises and ultrasound guided intratendinous PRP injection with eccentric exercises.
Follow-up- Follow-up (clinically and ultrasonographically) will be at 6, 12, 24 and 52 weeks. At 24 weeks, the researcher will be unblinded after the analysis of the preliminary data. The patients will remain blinded to the therapy until 52 weeks follow-up. At 52 weeks follow-up a second, blinded researcher will evaluate the patients using the primary and secondary outcome measurements.
Outcome measurements- Primary outcome measurement: VISA-A score, a validated instrument to detect the severity of symptoms in patients with Achilles tendinopathy. As secondary outcome measurements subjective patient satisfaction and return to sports will be rated. For the evaluation of tendon repair, Ultrasonographic Tissue Characterization (UTC) and Power Doppler ultrasound (PDU) will be performed. UTC was previously developed in horse tendons and provides quantitative information on tendon fiber alignment and the related ultra-structural integrity of the tendon tissue through a non-invasive approach.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Achilles Tendinopathy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
81 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Combination of eccentric exercises and injection of PRP
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Combination of eccentric exercises and physiological saline injection
Intervention Type
Biological
Intervention Name(s)
PRP Injection with eccentric exercises
Intervention Description
PRP Injection with eccentric exercises
Intervention Type
Biological
Intervention Name(s)
Placebo Injection with eccentric exercises
Intervention Description
Placebo Injection with eccentric exercises
Primary Outcome Measure Information:
Title
VISA-A Score
Time Frame
6, 12, 24 and 52 weeks
Secondary Outcome Measure Information:
Title
Ultrasonographic Tissue Characterization
Time Frame
6,12, 24 and 52 weeks
Title
Complications
Time Frame
Anytime
Title
Power doppler sound
Time Frame
6, 12, 24 and 52 weeks
Title
Patient satisfaction
Time Frame
6, 12, 24 and 52 weeks
Title
Return to sport
Time Frame
6, 12, 24 and 52 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria
Clinical diagnosis "chronic midportion Achilles tendinopathy"
Age 18-70 years
Exclusion criteria
Clinical suspicion of insertional disorders (pain at the site of the insertion of the Achilles tendon on the calcaneum)
Clinical suspicion of an Achilles tendon rupture (Thompson test abnormal and palpabel "gap")
Clinical suspicion of plantar flexor tenosynovitis (posteromedial pain when the toes are plantar flexed against resistance)
Clinical suspicion of n.suralis pathology (sensitive disorder in the area of the sural nerve)
Clinical suspicion of peroneal subluxation (visible luxation of the mm. Peroneï spot in combination with localized pain)
Suspicion of internal disorders: spondylarthropathy, gout, hyperlipidemia, Rheumatoid Arthritis and sarcoidosis.
Condition that prevents the patients from executing an active exercise programme
Patient has already performed eccentric exercises, according to the schedule of Alfredson et al (12 weeks)
Patient has already received an injection of PRP for this injury
Patient does not wish, for whatever reason, to undergo one of the two treatments
Known presence of a pregnancy
Condition of the Achilles tendon caused by medications (arising in relation to moment of intake), such as quinolones and statins
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
RJ De Vos, MD
Organizational Affiliation
Erasmus Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Erasmus Medical Center
City
Rotterdam
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
20068208
Citation
de Vos RJ, Weir A, van Schie HT, Bierma-Zeinstra SM, Verhaar JA, Weinans H, Tol JL. Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA. 2010 Jan 13;303(2):144-9. doi: 10.1001/jama.2009.1986.
Results Reference
derived
Learn more about this trial
The Value of Platelet-Rich Plasma in Chronic Midportion Achilles Tendinopathy: a Double-blind Randomized Clinical Trial
We'll reach out to this number within 24 hrs